Please assess the completion status of the following clinical trial:

Trial Title: Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* DNA proven CMT1A~* Muscle weakness in at least foot dorsiflexion (clinical assessment)~* Age between 18 and 65 years~* Male or non pregnant, non breastfeeding female~* CMT neuropathy score at screening ≤ 20~* Agrees to perform electrorophysiological studies and two cutaneous biopsies for determination of PMP22 expression and histology~* Providing signed written informed consent to participate in the study and willing and able to comply with all study procedures and scheduled visits~Exclusion Criteria:~* Patients with another neurological disease~* Patients using unauthorized concomitant treatments, ascorbic acid, opioids, levothyroxine and potentially neurotoxic drugs. Patients who can/agree to stop these medications 4 weeks before randomization can be included~* Patients who have participated in another trial of investigational drug within the past 30 days~* Concomitant major systemic disease~* Clinically significant history of unstable medical illness over the last 30 days (unstable angina...)~* History of significant hematologic, kidney, liver disease, or insulin-dependent diabetes~* Clinically significant abnormalities on the prestudy laboratory evaluation, physical evaluation, electrocardiogram (ECG)~* ASAT/ALAT levels above the upper limit of normal (ULN). However, patients with an isolated elevation of either ASAT or ALAT (\<1.5 ULN) can be included at investigators discretion if the remaining liver function tests are normal and if ASAT or ALAT value is stable at 2 distinct evaluations in the month prior to inclusion~* Serum creatinine levels above the upper limit of normal~* Limited mental capacity or psychiatric disease rendering the subject unable to provide written informed consent or comply with evaluation procedures~* History of recent alcohol or drug abuse or non-adherence with treatment or other experimental protocols~* Female of childbearing potential (apart of patient using adequate contraceptive measures), pregnant or breast feeding~* Suspected inability to complete the study follow-up (foreign workers, transient visitors, tourists or any others for whom follow-up evaluation is not assured)~* Limb surgery in the six months before randomization or planned before completion of the trial~* Known hypersensitivity to any of the individual components of PXT3003~* Porphyria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PXT3003 Low dose (Type: EXPERIMENTAL): Oral Liquid formulation, 1/100, bid, 12 months
- PXT3003 Intermediate dose (Type: EXPERIMENTAL): Oral Liquid formulation, 1/50, bid, 12 months
- PXT3003 High dose (Type: EXPERIMENTAL): Oral Liquid formulation, 1/10, bid, 12 months
- Placebo (Type: PLACEBO_COMPARATOR): Oral Liquid formulation, bid, 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).